Lumida
/TERN
⌘K
Terns Pharmaceuticals Inc

Terns Pharmaceuticals Inc

TERN
$52.95USD+0.04%+0.02 today

MARKET CAP

6.1B

P/E (TTM)

FWD P/E

DAY RANGE

$53 – $53

52W RANGE

$3
$53

AI Summary

Stalk
StalkMedium

TERN is in a clear Stage 2 advancing regime with a dominant higher highs & higher lows pattern and rising EMAs, but price is currently extended above structure and extreme overbought—medium-term bias remains bullish, yet short-term timing is neutral; wait for a pullback into the rising EMA zone before initiating longs.

  • Merck’s $6.7B all-cash deal at $53.00/share reflects strong premium
  • Deal closed May 5, 2026, minimizing acquisition uncertainty
  • Post-acquisition delisting halts TERN trading, stripping liquidity
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021TREND
Sales, Adj.$1.0M
YoY %
P / Sales160.5x
EV / Sales120.6x
Gross Profit, Adj.$1.0M
YoY %
Margin %100.0%
EV / Gross Profit120.6x
EBITDA, Adj.$-48.5M
YoY %
Margin %-4846.9%
EV / EBITDA-2.5x
EBIT$-49.9M
YoY %
Margin %-4986.0%
EV / EBIT-2.4x
Net Income$-50.2M
YoY %
Net Margin-5015.8%
EPS (GAAP)-$2.21
YoY %